Destiny Pharma's XF-73 achieved an "exceptionally high" 99.5% reduction in Staphylococcus aureus bacterial nasal carriage in a mid-stage trial, a result that should attract a number of potential partners for the UK firm.

Revealed: In Vivo’s list of 30 Rising Leaders across the biopharma, medtech and health technology sectors. Find out who made the cut. 

Japanese firm pays cash plus milestones for UK specialist as it looks to integrate novel screening platform and gain know-how in mitochondrial modulators with potential applications.

The world hopes a UK pilot can offer guidance on making novel antibiotics commercially viable, Summit Therapeutics CEO tells Scrip, but adds his lead asset won’t take part this time.